GIS:FRA
Gilead Sciences, Inc
129,22 €
arrow_upward
+0,54%(+0,70) 1 D
6. okt., 09:47:07 GMT+2 · EUR
search
Alle symboler
| Symbol | Pris | Endring | Endring (%) |
|---|
insights_autoGenererer viktig statistikk for GIS …
Åpne
128,92 €
Høy
129,22 €
Lav
128,92 €
Markedsverdi
178,30 mrd.
Snittvolum
419,00
Volum
10,00
52 u høy
134,58 €
52 u lav
96,21 €
Antall ansatte
17k
Åpne
128,92 €
Høy
129,22 €
Lav
128,92 €
Markedsverdi
178,30 mrd.
Snittvolum
419,00
Volum
10,00
52 u høy
134,58 €
52 u lav
96,21 €
Antall ansatte
17k
Nyhetssaker
Fra nettkilder og nyhetspartnere
AD HOC NEWS
·
for 2 timer siden
Gilead extends oncology deal. Gilead Sciences stock loses 1.01 percent.
Yahoo Finance
·
for 5 timer siden
Cognizant Expands AI-Enabled DevOps Capabilities for Gilead Sciences
Stock Titan
·
for 5 timer siden
Drugmaker Gilead gets AI support for selected tech programs under a five-year extension
MarketBeat
·
for 1 døgn siden
12,110 Gilead Sciences, Inc. $GILD Shares Sold by CapWealth Advisors LLC
Profil
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19. It also develops medicines in therapeutic areas such as oncology and inflammation and cell therapy.
In 1987, Michael L. Riordan founded the company under the name Oligogen. The original name was a reference to oligonucleotides, small strands of DNA used to target genetic sequences. Gilead held its initial public offering in 1992, and successfully developed drugs including Tamiflu and Vistide that decade.
In the 2000s, Gilead began evolving from a biotechnology company into a large pharmaceutical company, through acquisitions and investments, acquiring several subsidiaries. Gilead is a member of the Nasdaq-100 and the S&P 100.
The company has faced criticism over its business practices, including extremely high pricing of drugs such as Sovaldi and Truvada in the United States relative to production cost and cost in the developing world. Wikipedia
Om Gilead Sciences, Inc
Administrerende direktørDaniel O'Day
Ansatte17k
Grunnlagt22. juni 1987
HovedkontorFoster City, California, USA
Sektor-
Nettstedgilead.com